Population Pharmacokinetics of Imatinib in CML Patients in Iran
NCT ID: NCT02146846
Last Updated: 2016-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
170 participants
OBSERVATIONAL
2012-10-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00025415
Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia
NCT00947830
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
NCT02317159
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
NCT00066326
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
NCT01046487
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Imatinib, CML
Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
Imatinib
Patients with chronic myeloid leukemia who receive Imatinib as treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imatinib
Patients with chronic myeloid leukemia who receive Imatinib as treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no liver and renal failure
Exclusion Criteria
* previous treatment of interferon
* patients in blast or accelerated phase
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kerman University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ehsan Mohajeri
Assistant of Pharmaceutics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ehsan mohajeri, Ph.D.
Role: STUDY_DIRECTOR
Department of pharmaceutics, Faculty of pharmacy, Kerman University of medical sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shahid-Bahonar hospital
Kerman, Kerman, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Kerman-001-FOPPT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.